Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1991 Jul;46(7):512–523. doi: 10.1136/thx.46.7.512

Phosphodiesterase inhibitors: new opportunities for the treatment of asthma.

T J Torphy 1, B J Undem 1
PMCID: PMC463251  PMID: 1877039

Full text

PDF
512

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnes P. J. Endogenous catecholamines and asthma. J Allergy Clin Immunol. 1986 Jun;77(6):791–795. doi: 10.1016/0091-6749(86)90375-1. [DOI] [PubMed] [Google Scholar]
  2. Beavo J. A., Hardman J. G., Sutherland E. W. Hydrolysis of cyclic guanosine and adenosine 3',5'-monophosphates by rat and bovine tissues. J Biol Chem. 1970 Nov 10;245(21):5649–5655. [PubMed] [Google Scholar]
  3. Beavo J. A. Multiple isozymes of cyclic nucleotide phosphodiesterase. Adv Second Messenger Phosphoprotein Res. 1988;22:1–38. [PubMed] [Google Scholar]
  4. Beavo J. A., Reifsnyder D. H. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci. 1990 Apr;11(4):150–155. doi: 10.1016/0165-6147(90)90066-H. [DOI] [PubMed] [Google Scholar]
  5. Bergstrand H., Lundquist B. Partial purification and characterization of cyclic nucleotide phosphodiesterases from human bronchial tissue. Mol Cell Biochem. 1978 Oct 13;21(1):9–15. doi: 10.1007/BF00230191. [DOI] [PubMed] [Google Scholar]
  6. Billing B., Dahlqvist R., Garle M., Hörnblad Y., Ripe E. Separate and combined use of terbutaline and theophylline in asthmatics. Effects related to plasma levels. Eur J Respir Dis. 1982 Sep;63(5):399–409. [PubMed] [Google Scholar]
  7. Bobon D., Breulet M., Gerard-Vandenhove M. A., Guiot-Goffioul F., Plomteux G., Sastre-y-Hernández M., Schratzer M., Troisfontaines B., von Frenckell R., Wachtel H. Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives. Eur Arch Psychiatry Neurol Sci. 1988;238(1):2–6. doi: 10.1007/BF00381071. [DOI] [PubMed] [Google Scholar]
  8. Bourne H. R., Lichtenstein L. M., Melmon K. L., Henney C. S., Weinstein Y., Shearer G. M. Modulation of inflammation and immunity by cyclic AMP. Science. 1974 Apr 5;184(4132):19–28. doi: 10.1126/science.184.4132.19. [DOI] [PubMed] [Google Scholar]
  9. Bryson S. E., Rodger I. W. Effects of phosphodiesterase inhibitors on normal and chemically-skinned isolated airway smooth muscle. Br J Pharmacol. 1987 Nov;92(3):673–681. doi: 10.1111/j.1476-5381.1987.tb11371.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Busse W. W., Anderson C. L. The granulocyte response to the phosphodiesterase inhibitor RO 20-1724 in asthma. J Allergy Clin Immunol. 1981 Jan;67(1):70–74. doi: 10.1016/0091-6749(81)90048-8. [DOI] [PubMed] [Google Scholar]
  11. Church M. K., Featherstone R. L., Cushley M. J., Mann J. S., Holgate S. T. Relationships between adenosine, cyclic nucleotides, and xanthines in asthma. J Allergy Clin Immunol. 1986 Oct;78(4 Pt 2):670–675. doi: 10.1016/0091-6749(86)90044-8. [DOI] [PubMed] [Google Scholar]
  12. Colicelli J., Birchmeier C., Michaeli T., O'Neill K., Riggs M., Wigler M. Isolation and characterization of a mammalian gene encoding a high-affinity cAMP phosphodiesterase. Proc Natl Acad Sci U S A. 1989 May;86(10):3599–3603. doi: 10.1073/pnas.86.10.3599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Colucci W. S., Wright R. F., Braunwald E. New positive inotropic agents in the treatment of congestive heart failure. Mechanisms of action and recent clinical developments. 2. N Engl J Med. 1986 Feb 6;314(6):349–358. doi: 10.1056/NEJM198602063140605. [DOI] [PubMed] [Google Scholar]
  14. Cooper K. D., Kang K., Chan S. C., Hanifin J. M. Phosphodiesterase inhibition by Ro 20-1724 reduces hyper-IgE synthesis by atopic dermatitis cells in vitro. J Invest Dermatol. 1985 Jun;84(6):477–482. doi: 10.1111/1523-1747.ep12272486. [DOI] [PubMed] [Google Scholar]
  15. Elliott K. R., Berry J. L., Bate A. J., Foster R. W., Small R. C. The isoenzyme selectivity of AH 21-132 as an inhibitor of cyclic nucleotide phosphodiesterase activity. J Enzyme Inhib. 1991;4(3):245–251. doi: 10.3109/14756369109035848. [DOI] [PubMed] [Google Scholar]
  16. Fink G., Mittelman M., Shohat B., Spitzer S. A. Theophylline-induced alterations in cellular immunity in asthmatic patients. Clin Allergy. 1987 Jul;17(4):313–316. doi: 10.1111/j.1365-2222.1987.tb02020.x. [DOI] [PubMed] [Google Scholar]
  17. Foreman J. C., Hallett M. B., Mongar J. L. The relationship between histamine secretion and 45calcium uptake by mast cells. J Physiol. 1977 Sep;271(1):193–214. doi: 10.1113/jphysiol.1977.sp011996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Frossard N., Landry Y., Pauli G., Ruckstuhl M. Effects of cyclic AMP- and cyclic GMP- phosphodiesterase inhibitors on immunological release of histamine and on lung contraction. Br J Pharmacol. 1981 Aug;73(4):933–938. doi: 10.1111/j.1476-5381.1981.tb08748.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Godard P., Chaintreuil J., Damon M., Coupe M., Flandre O., Crastes de Paulet A., Michel F. B. Functional assessment of alveolar macrophages: comparison of cells from asthmatics and normal subjects. J Allergy Clin Immunol. 1982 Aug;70(2):88–93. doi: 10.1016/0091-6749(82)90234-2. [DOI] [PubMed] [Google Scholar]
  20. Godfrey R. W., Manzi R. M., Gennaro D. E., Hoffstein S. T. Phospholipid and arachidonic acid metabolism in zymosan-stimulated human monocytes: modulation by cAMP. J Cell Physiol. 1987 Jun;131(3):384–392. doi: 10.1002/jcp.1041310310. [DOI] [PubMed] [Google Scholar]
  21. Hall I. P., Donaldson J., Hill S. J. Modulation of carbachol-induced inositol phosphate formation in bovine tracheal smooth muscle by cyclic AMP phosphodiesterase inhibitors. Biochem Pharmacol. 1990 Apr 15;39(8):1357–1363. doi: 10.1016/0006-2952(90)90013-b. [DOI] [PubMed] [Google Scholar]
  22. Handslip P. D., Dart A. M., Davies B. H. Intravenous salbutamol and aminophylline in asthma: a search for synergy. Thorax. 1981 Oct;36(10):741–744. doi: 10.1136/thx.36.10.741. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Harris A. L., Connell M. J., Ferguson E. W., Wallace A. M., Gordon R. J., Pagani E. D., Silver P. J. Role of low Km cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig. J Pharmacol Exp Ther. 1989 Oct;251(1):199–206. [PubMed] [Google Scholar]
  24. Henkel-Tigges J., Davis R. L. Rat homologs of the Drosophila dunce gene code for cyclic AMP phosphodiesterases sensitive to rolipram and RO 20-1724. Mol Pharmacol. 1990 Jan;37(1):7–10. [PubMed] [Google Scholar]
  25. Johnson A. R. Human pulmonary endothelial cells in culture. Activities of cells from arteries and cells from veins. J Clin Invest. 1980 Apr;65(4):841–850. doi: 10.1172/JCI109736. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Kaliner M., Orange R. P., Austen K. F. Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. J Exp Med. 1972 Sep 1;136(3):556–567. doi: 10.1084/jem.136.3.556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Kuehl F. A., Jr, Zanetti M. E., Soderman D. D., Miller D. K., Ham E. A. Cyclic AMP-dependent regulation of lipid mediators in white cells. A unifying concept for explaining the efficacy of theophylline in asthma. Am Rev Respir Dis. 1987 Jul;136(1):210–213. doi: 10.1164/ajrccm/136.1.210. [DOI] [PubMed] [Google Scholar]
  28. Laitinen L. A., Laitinen A. Innervation of airway smooth muscle. Am Rev Respir Dis. 1987 Oct;136(4 Pt 2):S38–S42. doi: 10.1164/ajrccm/136.4_Pt_2.S38. [DOI] [PubMed] [Google Scholar]
  29. Leeman M., Lejeune P., Melot C., Naeije R. Reduction in pulmonary hypertension and in airway resistances by enoximone (MDL 17,043) in decompensated COPD. Chest. 1987 May;91(5):662–666. doi: 10.1378/chest.91.5.662. [DOI] [PubMed] [Google Scholar]
  30. Leikauf G. D., Ueki I. F., Nadel J. A., Widdicombe J. H. Bradykinin stimulates Cl secretion and prostaglandin E2 release by canine tracheal epithelium. Am J Physiol. 1985 Jan;248(1 Pt 2):F48–F55. doi: 10.1152/ajprenal.1985.248.1.F48. [DOI] [PubMed] [Google Scholar]
  31. Lichtenstein L. M., Margolis S. Histamine release in vitro: inhibition by catecholamines and methylxanthines. Science. 1968 Aug 30;161(3844):902–903. doi: 10.1126/science.161.3844.902. [DOI] [PubMed] [Google Scholar]
  32. Lincoln T. M. Cyclic GMP and mechanisms of vasodilation. Pharmacol Ther. 1989;41(3):479–502. doi: 10.1016/0163-7258(89)90127-7. [DOI] [PubMed] [Google Scholar]
  33. Livi G. P., Kmetz P., McHale M. M., Cieslinski L. B., Sathe G. M., Taylor D. P., Davis R. L., Torphy T. J., Balcarek J. M. Cloning and expression of cDNA for a human low-Km, rolipram-sensitive cyclic AMP phosphodiesterase. Mol Cell Biol. 1990 Jun;10(6):2678–2686. doi: 10.1128/mcb.10.6.2678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Lugnier C., Schoeffter P., Le Bec A., Strouthou E., Stoclet J. C. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol. 1986 May 15;35(10):1743–1751. doi: 10.1016/0006-2952(86)90333-3. [DOI] [PubMed] [Google Scholar]
  35. Macphee C. H., Harrison S. A., Beavo J. A. Immunological identification of the major platelet low-Km cAMP phosphodiesterase: probable target for anti-thrombotic agents. Proc Natl Acad Sci U S A. 1986 Sep;83(17):6660–6663. doi: 10.1073/pnas.83.17.6660. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Muggli R., Tschopp T. B., Mittelholzer E., Baumgartner H. R. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase. J Pharmacol Exp Ther. 1985 Oct;235(1):212–219. [PubMed] [Google Scholar]
  37. Murray K. J. Cyclic AMP and mechanisms of vasodilation. Pharmacol Ther. 1990;47(3):329–345. doi: 10.1016/0163-7258(90)90060-f. [DOI] [PubMed] [Google Scholar]
  38. Murray K. J., England P. J., Hallam T. J., Maguire J., Moores K., Reeves M. L., Simpson A. W., Rink T. J. The effects of siguazodan, a selective phosphodiesterase inhibitor, on human platelet function. Br J Pharmacol. 1990 Mar;99(3):612–616. doi: 10.1111/j.1476-5381.1990.tb12978.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Nicholson C. D., Challiss R. A., Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci. 1991 Jan;12(1):19–27. doi: 10.1016/0165-6147(91)90484-a. [DOI] [PubMed] [Google Scholar]
  40. Nielson C. P. Beta-adrenergic modulation of the polymorphonuclear leukocyte respiratory burst is dependent upon the mechanism of cell activation. J Immunol. 1987 Oct 1;139(7):2392–2397. [PubMed] [Google Scholar]
  41. Nielson C. P., Crowley J. J., Cusack B. J., Vestal R. E. Therapeutic concentrations of theophylline and enprofylline potentiate catecholamine effects and inhibit leukocyte activation. J Allergy Clin Immunol. 1986 Oct;78(4 Pt 1):660–667. doi: 10.1016/0091-6749(86)90086-2. [DOI] [PubMed] [Google Scholar]
  42. Nielson C. P., Crowley J. J., Morgan M. E., Vestal R. E. Polymorphonuclear leukocyte inhibition by therapeutic concentrations of theophylline is mediated by cyclic-3',5'-adenosine monophosphate. Am Rev Respir Dis. 1988 Jan;137(1):25–30. doi: 10.1164/ajrccm/137.1.25. [DOI] [PubMed] [Google Scholar]
  43. Nielson C. P., Vestal R. E., Sturm R. J., Heaslip R. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J Allergy Clin Immunol. 1990 Nov;86(5):801–808. doi: 10.1016/s0091-6749(05)80186-1. [DOI] [PubMed] [Google Scholar]
  44. Palmer J. B., Barnes P. J. Neuropeptides and airway smooth muscle function. Am Rev Respir Dis. 1987 Oct;136(4 Pt 2):S50–S54. doi: 10.1164/ajrccm/136.4_Pt_2.S50. [DOI] [PubMed] [Google Scholar]
  45. Persson C. G. Overview of effects of theophylline. J Allergy Clin Immunol. 1986 Oct;78(4 Pt 2):780–787. doi: 10.1016/0091-6749(86)90061-8. [DOI] [PubMed] [Google Scholar]
  46. Pittler S. J., Baehr W., Wasmuth J. J., McConnell D. G., Champagne M. S., vanTuinen P., Ledbetter D., Davis R. L. Molecular characterization of human and bovine rod photoreceptor cGMP phosphodiesterase alpha-subunit and chromosomal localization of the human gene. Genomics. 1990 Feb;6(2):272–283. doi: 10.1016/0888-7543(90)90567-e. [DOI] [PubMed] [Google Scholar]
  47. Plaut M., Marone G., Gillespie E. The role of cyclic AMP in modulating cytotoxic T lymphocytes. II. Sequential changes during culture in responsiveness of cytotoxic lymphocytes to cyclic AMP-active agents. J Immunol. 1983 Dec;131(6):2945–2952. [PubMed] [Google Scholar]
  48. Plaut M., Marone G., Thomas L. L., Lichtenstein L. M. Cyclic nucleotides in immune responses and allergy. Adv Cyclic Nucleotide Res. 1980;12:161–172. [PubMed] [Google Scholar]
  49. Poisner A. M. Direct stimulant effect of aminophylline on catecholamine release from the adrenal medulla. Biochem Pharmacol. 1973 Feb 15;22(4):469–476. doi: 10.1016/0006-2952(73)90288-8. [DOI] [PubMed] [Google Scholar]
  50. Polson J. B., Krzanowski J. J., Goldman A. L., Szentivanyi A. Inhibition of human pulmonary phosphodiesterase activity by therapeutic levels of theophylline. Clin Exp Pharmacol Physiol. 1978 Sep-Oct;5(5):535–539. doi: 10.1111/j.1440-1681.1978.tb00707.x. [DOI] [PubMed] [Google Scholar]
  51. Polson J. B., Krzanowski J. J., Szentivanyi A. Correlation between inhibition of a cyclic GMP phosphodiesterase and relaxation of canine tracheal smooth muscle. Biochem Pharmacol. 1985 Jun 1;34(11):1875–1879. doi: 10.1016/0006-2952(85)90301-6. [DOI] [PubMed] [Google Scholar]
  52. Polson J. B., Krzanowski J. J., Szentivanyi A. Inhibition of a high affinity cyclic AMP phosphodiesterase and relaxation of canine tracheal smooth muscle. Biochem Pharmacol. 1982 Nov 1;31(21):3403–3406. doi: 10.1016/0006-2952(82)90618-9. [DOI] [PubMed] [Google Scholar]
  53. Rasmussen H., Goodman D. B. Relationships between calcium and cyclic nucleotides in cell activation. Physiol Rev. 1977 Jul;57(3):421–509. doi: 10.1152/physrev.1977.57.3.421. [DOI] [PubMed] [Google Scholar]
  54. Reiser J., Yeang Y., Warner J. O. The effect of zaprinast (M&B 22,948, an orally absorbed mast cell stabilizer) on exercise-induced asthma in children. Br J Dis Chest. 1986 Apr;80(2):157–163. doi: 10.1016/0007-0971(86)90036-7. [DOI] [PubMed] [Google Scholar]
  55. Renz H., Gong J. H., Schmidt A., Nain M., Gemsa D. Release of tumor necrosis factor-alpha from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides. J Immunol. 1988 Oct 1;141(7):2388–2393. [PubMed] [Google Scholar]
  56. Robicsek S. A., Krzanowski J. J., Szentivanyi A., Polson J. B. High pressure liquid chromatography of cyclic nucleotide phosphodiesterase from purified human T-lymphocytes. Biochem Biophys Res Commun. 1989 Aug 30;163(1):554–560. doi: 10.1016/0006-291x(89)92173-6. [DOI] [PubMed] [Google Scholar]
  57. Rossing T. H., Drazen J. M. Effects of milrinone on contractile responses of guinea pig trachea, lung parenchyma and pulmonary artery. J Pharmacol Exp Ther. 1986 Sep;238(3):874–879. [PubMed] [Google Scholar]
  58. Rudd R. M., Gellert A. R., Studdy P. R., Geddes D. M. Inhibition of exercise-induced asthma by an orally absorbed mast cell stabilizer (M & B 22,948). Br J Dis Chest. 1983 Jan;77(1):78–86. [PubMed] [Google Scholar]
  59. Schneider H. H., Schmiechen R., Brezinski M., Seidler J. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol. 1986 Aug 7;127(1-2):105–115. doi: 10.1016/0014-2999(86)90210-4. [DOI] [PubMed] [Google Scholar]
  60. Schulman E. S., Adkinson N. F., Jr, Newball H. H. Cyclooxygenase metabolites in human lung anaphylaxis: airway vs. parenchyma. J Appl Physiol Respir Environ Exerc Physiol. 1982 Sep;53(3):589–595. doi: 10.1152/jappl.1982.53.3.589. [DOI] [PubMed] [Google Scholar]
  61. Seiler S., Arnold A. J., Grove R. I., Fifer C. A., Keely S. L., Jr, Stanton H. C. Effects of anagrelide on platelet cAMP levels, cAMP-dependent protein kinase and thrombin-induced Ca++ fluxes. J Pharmacol Exp Ther. 1987 Nov;243(2):767–774. [PubMed] [Google Scholar]
  62. Sevilla D. C., Dohrmann M. L., Somelofski C. A., Wawrzynski R. P., Wagner N. B., Wagner G. S. Invalidation of the resting electrocardiogram obtained via exercise electrode sites as a standard 12-lead recording. Am J Cardiol. 1989 Jan 1;63(1):35–39. doi: 10.1016/0002-9149(89)91072-2. [DOI] [PubMed] [Google Scholar]
  63. Silver P. J., Hamel L. T., Perrone M. H., Bentley R. G., Bushover C. R., Evans D. B. Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle. Eur J Pharmacol. 1988 May 20;150(1-2):85–94. doi: 10.1016/0014-2999(88)90753-4. [DOI] [PubMed] [Google Scholar]
  64. Small R. C., Berry J. L., Boyle J. P., Chapman I. D., Elliott K. R., Foster R. W., Watt A. J. Biochemical and electrical aspects of the tracheal relaxant action of AH 21-132. Eur J Pharmacol. 1991 Jan 17;192(3):417–426. doi: 10.1016/0014-2999(91)90234-h. [DOI] [PubMed] [Google Scholar]
  65. Souness J. E., Brazdil R., Diocee B. K., Jordan R. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine. Br J Pharmacol. 1989 Nov;98(3):725–734. doi: 10.1111/j.1476-5381.1989.tb14599.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  66. Sturgess I., Searle G. F. The acute toxic effect of the phosphodiesterase inhibitor rolipram on plasma osmolality. Br J Clin Pharmacol. 1990 Mar;29(3):369–370. doi: 10.1111/j.1365-2125.1990.tb03651.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Svedmyr K., Svedmyr N. Does theophylline potentiate inhaled beta 2-agonists? Allergy. 1982 Feb;37(2):101–110. doi: 10.1111/j.1398-9995.1982.tb01883.x. [DOI] [PubMed] [Google Scholar]
  68. Svedmyr N., Svedmyr K. In-vitro and in-vivo effects of theophylline and beta 2-adrenostimulants in combination. Eur J Respir Dis Suppl. 1980;109:83–91. [PubMed] [Google Scholar]
  69. Swinnen J. V., Joseph D. R., Conti M. Molecular cloning of rat homologues of the Drosophila melanogaster dunce cAMP phosphodiesterase: evidence for a family of genes. Proc Natl Acad Sci U S A. 1989 Jul;86(14):5325–5329. doi: 10.1073/pnas.86.14.5325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Takenawa T., Ishitoya J., Nagai Y. Inhibitory effect of prostaglandin E2, forskolin, and dibutyryl cAMP on arachidonic acid release and inositol phospholipid metabolism in guinea pig neutrophils. J Biol Chem. 1986 Jan 25;261(3):1092–1098. [PubMed] [Google Scholar]
  71. Thompson W. J., Appleman M. M. Characterization of cyclic nucleotide phosphodiesterases of rat tissues. J Biol Chem. 1971 May 25;246(10):3145–3150. [PubMed] [Google Scholar]
  72. Torphy T. J., Burman M., Huang L. B., Tucker S. S. Inhibition of the low km cyclic AMP phosphodiesterase in intact canine trachealis by SK&F 94836: mechanical and biochemical responses. J Pharmacol Exp Ther. 1988 Sep;246(3):843–850. [PubMed] [Google Scholar]
  73. Torphy T. J., Cieslinski L. B. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle. Mol Pharmacol. 1990 Feb;37(2):206–214. [PubMed] [Google Scholar]
  74. Torphy T. J., Zhou H. L., Burman M., Huang L. B. Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis. Mol Pharmacol. 1991 Mar;39(3):376–384. [PubMed] [Google Scholar]
  75. Undem B. J., Graziano F. M., Buckner C. K. Effects of isoproterenol on histamine release induced from monodispersed guinea-pig lung cells by different secretagogues. J Pharmacol Exp Ther. 1985 Jun;233(3):617–622. [PubMed] [Google Scholar]
  76. Undem B. J., Peachell P. T., Lichtenstein L. M. Isoproterenol-induced inhibition of immunoglobulin E-mediated release of histamine and arachidonic acid metabolites from the human lung mast cell. J Pharmacol Exp Ther. 1988 Oct;247(1):209–217. [PubMed] [Google Scholar]
  77. Undem B. J., Torphy T. J., Goldman D., Chilton F. H. Inhibition by adenosine 3':5'-monophosphate of eicosanoid and platelet-activating factor biosynthesis in the mouse PT-18 mast cell. J Biol Chem. 1990 Apr 25;265(12):6750–6758. [PubMed] [Google Scholar]
  78. Wachtel H. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3',5'-monophosphate phosphodiesterase inhibitors. Neuropharmacology. 1983 Mar;22(3):267–272. doi: 10.1016/0028-3908(83)90239-3. [DOI] [PubMed] [Google Scholar]
  79. Weishaar R. E., Cain M. H., Bristol J. A. A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537–545. doi: 10.1021/jm50001a001. [DOI] [PubMed] [Google Scholar]
  80. Weiss B. Differential activation and inhibition of the multiple forms of cyclic nucleotide phosphodiesterase. Adv Cyclic Nucleotide Res. 1975;5:195–211. [PubMed] [Google Scholar]
  81. Wells J. N., Hardman J. G. Cyclic nucleotide phosphodiesterases. Adv Cyclic Nucleotide Res. 1977;8:119–143. [PubMed] [Google Scholar]
  82. White J. R., Ishizaka T., Ishizaka K., Sha'afi R. Direct demonstration of increased intracellular concentration of free calcium as measured by quin-2 in stimulated rat peritoneal mast cell. Proc Natl Acad Sci U S A. 1984 Jul;81(13):3978–3982. doi: 10.1073/pnas.81.13.3978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Wood M. A., Hess M. L. Long-term oral therapy of congestive heart failure with phosphodiesterase inhibitors. Am J Med Sci. 1989 Feb;297(2):105–113. doi: 10.1097/00000441-198902000-00006. [DOI] [PubMed] [Google Scholar]
  84. Zurier R. B., Weissmann G., Hoffstein S., Kammerman S., Tai H. H. Mechanisms of lysosomal enzyme release from human leukocytes. II. Effects of cAMP and cGMP, autonomic agonists, and agents which affect microtubule function. J Clin Invest. 1974 Jan;53(1):297–309. doi: 10.1172/JCI107550. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES